Charcot-Marie-Tooth
CP-301
CP-301 is a discovery program run in collaboration with Vernalis. Here, Contera Pharma aims to develop a first-in-class small-molecule modulator of RNA splicing events critical for the development of disease.
About Charcot-Marie-Tooth
Charcot-Marie-Tooth (CMT) disease is a group of inherited peripheral neuropathies characterized by progressive degeneration of motor and sensory nerves. This leads to muscle weakness, atrophy, and sensory loss, primarily in the extremities. The disease is caused by mutations in genes involved in the structure and function of peripheral nerves, affecting myelin sheath or axonal integrity. CMT is one of the most common inherited neurological disorders. Specifically, CMT1A, the most common subtype, affects about 1 in 5,000 people. Caused by a duplication of the PMP22 gene, it disrupts peripheral nerve function, leading to muscle weakness, especially in the legs and feet, and foot deformities like high arches. Symptoms typically start in adolescence, including difficulty walking and reduced reflexes. While there is no cure, physical therapy, orthotics, and pain management can help manage symptoms. Life expectancy remains normal, though the condition impacts daily life.
Recent News
December 03, 2024
Contera Pharma Welcomes New Board Members to Drive Strategic Growth
[Hørsholm, Denmark – December 03, 2024] – Contera Pharma A/S, a clinical-stage biotech company pioneering treatments for neurological disorders, is proud to…
Read more
November 28, 2024
Contera Pharma announces first patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease
Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the dosing of the first patient in…
Read more
Contact us
Contera Pharma
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com